Patents by Inventor Deqiang Niu

Deqiang Niu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF IN NEURODEGENERATIVE DISEASES
    Publication number: 20230414581
    Abstract: Provided in the present disclosure is the use of an SARM1 enzyme activity inhibitor in the treatment of neurodegenerative diseases or neurological diseases or conditions, and in particular, provided in the present invention are a compound represented by formula (a) as an SARM1 enzyme activity inhibitor, and a pharmaceutical composition thereof.
    Type: Application
    Filed: November 9, 2021
    Publication date: December 28, 2023
    Applicant: ARTIVILA BIOPHARMA
    Inventors: Deqiang NIU, Zhendong ZHU, Yongjuan ZHAO, Wanhua LI
  • HETEROCYCLIC PAD4 INHIBITORS
    Publication number: 20230167131
    Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 1, 2023
    Inventors: Kumaravel Selvakumar, Venkatram Paidi, Srinivasan Thangathirupathy, Vijaya Kumar Cm, Tirupathi Rao Alajangi, Mallikarjun Reddy Sura, Krishna Mahadevu, Ramesh Kumar Sistla, Piyush Agarwal, Arul Mozhi Subbiah Karuppiah, Jalathi S. Nair, Ooha Morampudi, Manoranjan Panda, Joseph A. Tino, Robert J. Cherney, John V. Duncia, Daniel S. Gardner, T. G. Murali Dhar, Audrey Graham Ross, Paul E. Gormisky, Xiao Zhu, Boris M. Seletsky, Alyssa H. Antropow, Deqiang Niu, Zhengdong Zhu, Guobin Miao, Julio Herman Cuervo
  • MK2 inhibitors and uses thereof
    Patent number: 11584757
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: February 21, 2023
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • Ligand-directed covalent modification of protein
    Patent number: 11542492
    Abstract: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: January 3, 2023
    Assignee: Celgene CAR LLC
    Inventors: Russell C. Petter, Charles F. Jewell, Kwangho Lee, Aravind Prasad Medikonda, Deqiang Niu, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20220332687
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 20, 2022
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE
    Publication number: 20220251079
    Abstract: Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.
    Type: Application
    Filed: May 15, 2020
    Publication date: August 11, 2022
    Inventors: Bryce K. ALLEN, Brian T. CHAMBERLAIN, Timothy A. DWIGHT, Huang HUANG, Meghana M. KULKARNI, Zhixiong LIN, Kristen A. MARINO, Deqiang NIU, Sharon SHECHTER, Steven SWANN
  • OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE
    Publication number: 20220227761
    Abstract: Compounds of Formulae I, II, their pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formulae I or II as effective modulators of STING are also provided.
    Type: Application
    Filed: May 15, 2020
    Publication date: July 21, 2022
    Inventors: Bryce K. ALLEN, Brian T. CHAMBERLAIN, Timothy A. DWIGHT, Huang HUANG, Zhixiong LIN, Kristen A. MARINO, Deqiang NIU, Sharon SHECHTER, Steven SWANN
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220218704
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 20, 2021
    Publication date: July 14, 2022
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Matthew Frank Baevsky, Juswinder Singh
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 11351168
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: June 7, 2022
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • MK2 inhibitors and uses thereof
    Patent number: 11098061
    Abstract: The present invention provides compounds of formula V: or pharmaceutically acceptable salts thereof, useful as inhibitors of MK2 kinases, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
  • Heterocyclic compounds and uses thereof
    Patent number: 11096942
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: August 24, 2021
    Assignee: Celgene CAR LLC
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Matthew Frank Baevsky, Juswinder Singh
  • MK2 INHIBITORS AND USES THEREOF
    Publication number: 20210053984
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 27, 2020
    Publication date: February 25, 2021
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Patent number: 10828300
    Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 10, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Heteroaryl compounds and uses thereof
    Patent number: 10774052
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: September 15, 2020
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20200276194
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 4, 2019
    Publication date: September 3, 2020
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Matthew Frank Baevsky, Juswinder Singh
  • Protein kinase conjugates and inhibitors
    Patent number: 10662195
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: May 26, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
    Patent number: 10618902
    Abstract: The present invention provides substituted pyrido[2,3-d]pyrimidine compounds useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: April 14, 2020
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 10596172
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 24, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • MK2 inhibitors and uses thereof
    Patent number: 10577380
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: March 3, 2020
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190375719
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 23, 2019
    Publication date: December 12, 2019
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson